Acute Effect of Erythropoietin on Endothelin Release in Uremia
Author(s) -
Ank Nurol,
Adam Bahattin,
Kandemir Tolga,
Tekin Akpolat,
Bedir Abdülkerim
Publication year - 1996
Publication title -
the nephron journals/nephron journals
Language(s) - English
Resource type - Journals
eISSN - 2235-3186
pISSN - 1660-8151
DOI - 10.1159/000188980
Subject(s) - medicine , citation , icon , nephrology , library science , computer science , programming language
Dr. Arik Nurol, Ondokuz Mayis Universitesi, Tip Fakültesi, Nefrologi Bölümü, Kurupelit, TR-55139 Samsun (Turkey) p > 0.05 travenously at a single dose of 75 U/kg. Blood samples for ET-1 determination were taken at 15, 30, and 60 min after injection. Blood pressure readings were recorded simultaneously. Plasma ET-1 levels were measured by the ELISA technique (Amersham, UK). The statistical significance of the alterations in ET-1 concentration and blood pressure readings throughout the study was determined by Friedman two-way ANOVA test. Dear Sir, The correction of anemia by recombi-nant human erythropoietin (rH-Epo) in ure-mic patients may exacerbate hypertension in some hypertensive patients or raises blood pressure in some previously normotensive subjects [1-4]. But the underlying mechanism has not yet been clarified and various causes such as increased blood viscosity and total red cell mass inducing an increase in peripheral resistance [5] and reversal of compensatory vasodilatation induced by renal anemia [6] have been proposed before in several studies. Regarding the pathogenetic factors causing increased systemic vascular resistance during rH-Epo therapy, some other mechanisms such as activation of neurohumoral systems and imbalance of local endothelial factors have been proposed in recent years [7]. Although the presence of some reports suggesting the direct relationship between rH-Epo injection and increased endothelin-1 (ET-1) levels and blood pressure [8-11], a final clear-cut conclusion has not yet been drawn. In order to evaluate the acute effect of rH-Epo injection on ET-1 release in ure-mic patients, we studied plasma ET-1 levels after a single-dose i.v. rH-Epo administration in 10 predialysis patients. We included 10 patients with chronic renal failure, previously untreated by dialysis (mean age 45 years, range 29-58; 6 females, 5 males). The patients had never taken rH-Epo before. After the baseline sampling, rH-Epo (Eprex®‚Cilag, Switzerland) was given in-
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom